KBI Biopharma Announces Subcontract with Mapp Biopharmaceutical on Sudan ebolavirus Treatment
Products
KBI Biopharma, Inc., a JSR Life Sciences company, has announced it entered into a subcontract with Mapp Biopharmaceutical, Inc. for the continued development and manufacturing of MBP134, an experimental combination monoclonal antibody treatment for Sudan ebolavirus.
For details, please see the announcement from JSR Life Sciences LLC on URL.